Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Adagio Medical Holdings (ADGM) EBITDA (2023 - 2026)

Adagio Medical Holdings has reported EBITDA over the past 4 years, most recently at -$7.0 million for Q1 2026.

  • Quarterly EBITDA rose 9.45% to -$7.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$24.4 million through Mar 2026, down 36.4% year-over-year, with the annual reading at -$25.2 million for FY2025, 53.16% up from the prior year.
  • EBITDA was -$7.0 million for Q1 2026 at Adagio Medical Holdings, down from -$3.3 million in the prior quarter.
  • Over five years, EBITDA peaked at $3.6 million in Q3 2024 and troughed at -$10.8 million in Q3 2023.
  • The 4-year median for EBITDA is -$7.4 million (2025), against an average of -$6.2 million.
  • Year-over-year, EBITDA surged 133.44% in 2024 and then plummeted 381.18% in 2025.
  • A 4-year view of EBITDA shows it stood at -$8.6 million in 2023, then soared by 141.68% to $3.6 million in 2024, then crashed by 192.02% to -$3.3 million in 2025, then crashed by 112.66% to -$7.0 million in 2026.
  • Per Business Quant, the three most recent readings for ADGM's EBITDA are -$7.0 million (Q1 2026), -$3.3 million (Q4 2025), and -$10.1 million (Q3 2025).